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Objective: Prophylactic replacement of Bjo¨rk-Shiley convexo-concave valves
(Shiley, Inc., Irvine, Calif.) has been advised for selected groups of patients.
If prophylactic replacement is considered, risks of postoperative morbidity
and mortality have to be weighed against benefits of replacement. Here we
report the results of prophylactic replacement of Bjo¨rk-Shiley convexo-
concave valves at risk of strut fracture in The Netherlands. Methods: We
reviewed medical records of 36 patients undergoing prophylactic replace-
ment of their Bjo¨rk-Shiley convexo-concave valves before August 1995.
Replacement was judged to be prophylactic if the risk of strut fracture
outweighed that of death from reoperation, or the patient wished to have
the valve replaced although it was not recommended. The procedure was
also considered to be prophylactic if a concomitant pathologic condition,
not likely to require cardiac surgery in the near future, was present or if
preoperative examination revealed an unexpected cardiac pathologic con-
dition. Results: Twenty-two 70-degree and 16 60-degree Bjo¨rk-Shiley con-
vexo-concave valves and one spherical valve were replaced (25 aortic and 14
mitral, including three double-valve replacements). Early mortality was
2.8% (1/36) (exact 95% confidence interval [CI] 0.1 to 14.5). Mean follow-up
was 33 months. One- and 3-year survivals were 94% (95% CI 79% to 99%)
and 91% (95% CI 74% to 97%), respectively. All three deaths were sudden.
Conclusions: If special care is taken in selecting patients, the risk of
prophylactic replacement is comparable to that of primary valve replace-
ment. More data are needed to assess whether the risk of sudden death is
possibly increased. (J Thorac Cardiovasc Surg 1998;115:577-81)
Replacement of prosthetic heart valves in generalcarries a higher risk of death and morbidity than
primary valve replacement.1, 2 For some recipients
of the Bjo¨rk-Shiley convexo-concave (BScc) valve
(Shiley, Inc., Irvine, Calif.), nevertheless, the risk of
fracture of the outlet strut of their valve(s) may
outweigh the risk of mortality and morbidity associ-
ated with valve replacement, and prophylactic re-
placement has been recommended.3-8 The risk of
prophylactic replacement, however, is unknown.
Since 1991, several Dutch recipients of the BScc
valve were reoperated on based on the results of the
Dutch BScc follow-up study,3 a decision analysis of
the data,7 or sometimes the explicit wish of a patient
to have the valve explanted.
In this study we report on perioperative morbidity
and mortality and long-term survival in patients who
had prophylactic replacement of their BScc valve in
The Netherlands.
Patients and methods
Patients. Data were recorded at all cardiac surgery
centers in The Netherlands. All patients who underwent
prophylactic replacement of their BScc valve before Au-
gust 1995 were included in this study. If documented, the
considerations, including a possible formal decision anal-
ysis7 for the prophylactic replacement of each of the BScc
valve(s), were recorded from the patient records and a
comprehensive clinical profile, including relevant aspects
of the medical history, details of physical examination,
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cardiac catheterization and/or echocardiography, and, if
performed, coronary angiography. Also, the type of sur-
gical procedure, possible concomitant procedures, periop-
erative, and postoperative complications were recorded.
Prophylactic replacement. A replacement was judged
to be prophylactic if either the treating cardiac surgeon or
cardiologist considered the risk of outlet strut fracture for
that individual patient higher than his or her risk of death
from reoperation, or if the patient wished to have the
valve replaced although replacement was not directly
advised by his or her cardiac surgeon and cardiologist. If
a concomitant pathologic condition was already present
before replacement of the valve was considered, but was
not likely to require cardiac surgery in the near future, the
reoperation was still considered prophylactic. This was
also true if preoperative examination revealed an unex-
pected cardiac pathologic condition.
Follow-up. Follow-up data on functional and vital sta-
tus were collected from the clinical records and the
municipality registers. Early mortality was defined as
death occurring within 30 days or before hospital dis-
charge. The cause of death was determined on the basis of
medical records from the hospital (including autopsy
reports if present) or the patient’s general practitioner.
Table I. Characteristics of patients that underwent prophylactic replacement
Sex Age
Valve
Primary
reason
Secondary
reason
Medical history and
preoperative findings
Concomitant
surgery
Perioperative
complications
Follow-
up StatusPosition
Angle
(degree) Size
Male 26 A 60 21 R — — — — 8 days Dead
Female 68 A 60 21 R — — — — 22 mo Alive
Male 41 A 60 23 R PVL History of endocarditis — — 25 mo Alive
Male 63 A 60 23 R — — — — 39 mo Alive
Female 29 A 60 25 R PVL Marfan’s disease — — 17 mo Alive
VSD closed (1975)
Enlargement of aortic
valve (1978)
Male 35 A 60 25 W PVL History of endocarditis — Complete
AV block
(pacemaker
necessary)
29 mo Alive
Male 40 A 60 25 R — Prior reoperation for
PVL (1983)
Reconstruction
anterior mi-
tral leaflet
— 22 mo Alive
Preoperative finding:
PVL
Male 46 A 60 27 R — History of endocarditis — 14 mo Alive
Male 51 A 60 27 W — Strut fracture mitral
valve (1990) with
complicated postop-
erative course*
— — 45 mo Alive
Male 41 A 60 29 R — — — — 35 mo Alive
Female 47 M 60 27 R — — — — 24 mo Dead
Female 46 M 60 31 R — — — — 19 mo Alive
Female 58 M 60 31 W — — — — 34 mo Alive
Male 36 A 60 23 — — — — 30 mo Alive
M 60 31 R
Female 40 A Spherical 19 — — — Transfusion re-
action—multi-
organ failure
and excessive
bleeding
42 mo Alive
M 60 27 R
Male 47 A 70 23 R — — — — 3 mo Alive
Male 54 A 70 23 W — — — — 89 mo Alive
Male 26 A 70 27 R PVL — Replacement
aortic root
— 34 mo Alive
Male 42 A 70 27 R — — — Prolonged unex-
plained fever
and acute
hepatitis
41 mo Alive
A, Aortic; AV, atrioventricular; CAD, coronary artery disease; M, mitral; PVL, paravalvular leakage; R, high fracture risk; TIA, transient ischemic attack; VSD,
ventricular septal defect; W, patient’s explicit wish to have the valve explanted.
*The BScc aortic valve was not replaced during the emergency procedure after strut fracture of the mitral valve in 1990.
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Data analysis. Proportions are presented with an exact
95% CI.9 Cumulative survival was estimated by the
Kaplan-Meier product limit method.10
Results
Until August 1995 37 Dutch BScc valve recipients
from nine centers underwent prophylactic replace-
ment of their valves; on one surviving patient no
further data were available. The BScc valves of 29
patients were explanted because the treating cardiac
surgeon and cardiologist thought that prophylactic
replacement compared favorably with expectant
management; formal decision analysis was used to
support this decision in nine of these patients. Seven
patients insisted on having their valves replaced,
although replacement was not directly recom-
mended by their physicians.
Table I shows patient and surgical characteristics.
The series consisted of 23 men and 13 women. The
mean age was 49 years (612 standard deviation;
extremes 26 to 68 years). Five patients had a history
of endocarditis. Before reoperation, all patients
were in New York Heart Association functional
class I or II. At preoperative screening, angiography
demonstrated severe tricuspid regurgitation in one
patient, coronary artery disease in two patients, and
paravalvular leakage in five patients.
Twenty-two aortic valve replacements, 11 mitral
valve replacements, and three double-valve replace-
ments were performed. Ten large-size ($29 mm)
Table I. Cont’d
Sex Age
Valve
Primary
reason
Secondary
reason
Medical history and
preoperative findings
Concomitant
surgery
Perioperative
complications
Follow-
up StatusPosition
Angle
(degree) Size
Male 50 A 70 27 R — — — — 36 mo Alive
Male 54 A 70 27 R — Amaurosis fugax (1970) — — 32 mo Alive
Male 60 A 70 27 R — — — Complete
AV block
(pacemaker
necessary)
35 mo Alive
Male 64 A 70 27 R — — — — 47 days Dead
Male 66 A 70 27 R — — — — 40 mo Alive
Male 48 A 70 29 W — — — — 39 mo Alive
Male 62 A 70 29 W — — — — 90 mo Alive
Male 66 A 70 29 R — — — — 36 mo Alive
Female 43 M 70 27 R — — — — 25 days Alive
Female 47 M 70 27 R — History of myocardial
infarction, TIA, and
lung embolism; open
commisurotomy mi-
tral valve (1978);
severe tricuspid re-
gurgitation
— — 41 mo Alive
Female 30 M 70 29 R — Prior mitral valve re-
placement (1979)
— — 32 mo Alive
Female 53 M 70 29 R — — — — 41 mo Alive
Female 65 M 70 29 R — — — — 44 mo Alive
Male 46 M 70 31 R — Prior mitral valve re-
placement (1979);
history of endocardi-
tis
— — 17 mo Alive
Female 63 M 70 31 R — Closed commisur-
otomy mitral valve
(1958)
— — 39 mo Alive
Female 64 M 70 31 R — TIA (1978); CAD Coronary ar-
tery bypass
grafting
— 38 mo Alive
Male 66 A 70 25 W — History of endocardi-
tis; CAD
Coronary ar-
tery bypass
grafting
— 38 mo Alive
M 70 29
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and 12 small-size (,29 mm) 70-degree BScc valves
and four large-size and 12 small-size 60-degree BScc
valves were replaced. Concomitant procedures com-
prised tricuspid valve plasty in one patient, coronary
artery bypass grafting in two patients, reconstruction
of the previously damaged anterior mitral leaflet in
one patient, and replacement of the aortic root by a
homograft in one patient.
All patients survived the reoperation without
technical problems. Four patients had postoperative
complications (Table I). At hospital discharge no
persistent neurologic deficits were documented. The
median length of hospital stay was 11 days and
ranged from 8 days to 267 days. The mean follow-up
was 33 months (extremes 8 days to 90 months).
One patient died (2.8%, exact 95% CI 0.1% to
14.5%), 8 days after the operation after just having
been released from the hospital. Two patients died
later during follow-up at 47 days and at 745 days,
respectively. All three patients died suddenly. An
autopsy was performed in one of these deaths and
no cause of death could be determined. The survival
was 94% at 12 months (95% CI 79% to 99%) and
declined to 91% at 36 months (95% CI 74% to
97%).
Discussion
The patients described in this study represent a
carefully selected group of patients because the
treating cardiac surgeon weighed the risk of outlet
strut fracture against the individual risk of morbidity
or mortality from reoperation for each of these
patients to the best of his or her abilities. The risk
estimates applied by the cardiac surgeons were
based on the available literature at that time3, 6-8, 11-14
and on institution-specific experiences with rere-
placement of prosthetic heart valves. Except for the
patients who wished to have their valve replaced, the
cardiac surgeons believed the risk of outlet strut
fracture outweighed that reoperation. The fact that
decision analytic support was used for only nine
patients to support the decision to explant the BScc
valve does not mean that the decision making was
less prudent in the other patients; it merely reflects
the decision process in clinical practice and under-
scores the fact that many obstacles to the under-
standing and acceptance of formal decision analysis
still exist.15-17
The results from our study add significantly to the
understanding of risks associated with prophylactic
replacement of artificial valves after several other
studies with subgroups of similarly young patients
undergoing elective valve reoperation have been
published.13, 18 Contrary to patients undergoing pro-
phylactic replacement, those undergoing elective
replacement always have some underlying heart
condition requiring valve replacement at that mo-
ment. Furthermore, in contrast to our study, these
studies only reported on in-hospital mortality. Little
has been written on the operative risk associated
with prophylactic replacement of artificial heart
valves. The few studies that actually dealt with
prophylactic replacement of well-functioning artifi-
cial heart valves concerned Braunwald-Cutter aortic
prostheses (Cutter Biological, Berkeley, Calif.) and
date almost 20 years back.11, 12 Prophylactic replace-
ment of these valves, because of predicted failure,
seemed to be associated with a low risk of periop-
erative mortality. In the past prophylactic replace-
ment of BScc valves was advised for selected groups
of patients.3, 4, 7 Some authors have claimed that
elective replacement of BScc valves, because of its
inherent morbidity and mortality, cannot be recom-
mended.19-21 Other clinical studies, however, have
suggested that reoperative valvular surgery in an
elective setting has perioperative morbidity and
mortality similar to initial valve replacement.12-14, 18
Early mortality in this study was similar to that of
primary valve replacement in our original cohort3
and in accordance with what was assumed in several
decision analyses4, 7 and therefore seems acceptable,
especially because six patients (17%) were reoper-
ated on previously. However, the one patient who
died early was a 26-year-old man in perfect health
before the operation. The sudden death of another
64-year-old patient, 47 days after the operation,
most likely was also related to the procedure. If this
death would be accounted for as operative death,
the operative mortality would increase to 5.6%
(95% exact CI 0.7% to 18.7%). Furthermore, all
deaths in this study were sudden. Sudden death has
been found to be the second most common mode of
death in patients undergoing primary valve replace-
ment.1 Despite the small number of events, the
sudden death rate in this study during the first year
of follow-up was 7.8 (95% CI 1.8% to 34.0%; Cox
regression) times higher than in our original cohort
study.3 Given the small number of patients in this
study, it remains highly speculative whether this was
a chance finding or whether prophylactic replace-
ment really carries a higher risk of sudden death.
More data are needed to assess the risk of sudden
death after prophylactic replacements. On the other
hand, BScc valves still fracture. Forty-six fractures
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had been documented until August 1995. Six large
fractures ($29 mm) 60-degree BScc valves (five
mitral and one aortic) were reported after the
closing date of this study.
Thus prophylactic replacement still seems advis-
able for selected subgroups of BScc valve recipients,
but evidence from this study indicates that proper
decision making is warranted.
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Appendix
Participating centers: Academisch Medisch Centrum
(BAJM de Mol; 2 patients), Onze Lieve Vrouwe Gasthuis
Amsterdam (L Eijsman; 11 patients), Academisch Ziek-
enhuis Leiden (H Huysmans; 1 patient), Dijkzigt Zieken-
huis Rotterdam (LA van Herwerden; 5 patients), Acade-
misch Ziekenhuis Utrecht (JJ Bredee; 1 patient), Sint
Antonius Ziekenhuis Nieuwegein (JJAMT Defauw; 12
patients), Medisch Centrum de Klokkenberg (ThR van
Geldorp; 3 patients), Ziekenhuis de Weezenlanden
Zwolle (MMP Haalebos; 1 patient).
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